Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
Toll-like receptor ligands act as adjuvants in allergen-specific immunotherapy
February 8th, 2006
Toll-like receptor ligands act as adjuvants in allergen-specific immunotherapy. "Allergen-specific immunotherapy (SIT) leads to long-term amelioration of T-helper type 2 (Th2)-mediated allergic symptoms and is therefore recommended as a first line therapy for allergies. The major disadvantage of SIT is its low efficiency, requiring treatment over years. In this study, we evaluated the potential of Toll-like receptor (TLR) ligands to facilitate Th1-type immune responses," researchers in Switzerland and the United States report. "The immunogenicity and therapeutic potential of the major bee venom allergen phospholipase A2 (PLA2) combined with various...
Source: Immunotherapy Weekly (2006-02-08)
|
